drugset / Trial / NCT04140318
Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Phase 2
Unknown
60 enrolled
Chinese Academy of Medical Sciences
Beijing Friendship Hospital · collabBeijing Hospital · collabChinese PLA General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Sintilimab (PD-1 inhibitor) and nab-paclitaxel in second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. This is a prospective, multi-centers, single arm phase II trial with primary objective overall response rate and second objective of safety and other efficacy endpoints.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2022-08-30
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |